OBJECTIVES: Tachycardia-induced cardiomyopathy (TCM) is a reversible cause of heart failure. Little is known of the characteristics of tachycardia associated with the development of left ventricular (LV) dysfunction and the reversal of cardiomyopathy after cure of tachycardia. This study aimed to examine the reversal of cardiomyopathy in patients undergoing ablation with congestive heart failure secondary to tachycardia. METHODS: A total of 625 patients underwent radiofrequency ablation for tachycardiarrhymias between January 2009 and July 2011. Echocardiography analysis was performed to identify patients with depressed LV function, defined as a left ventricular ejection fraction <50 %. Patients with preexisting structural heart disease (n = 10) were excluded. NT-pro-B-type natriuretic peptide (NT-proBNP) assessment was performed before ablation in patients considered to have TCM (n = 17). Repeated echocardiography study and NT-proBNP assessment were measured after a mean follow-up of 3 months. Levels of NT-proBNP before and after ablation were compared. Reversal of cardiomyopathy was also assessed. RESULTS: The incidence of TCM was 2.7 % (12 males; age, 35.8 ± 17.1 years). Successful ablation was performed in 16 of 17 patients (94.1 %). There was a significant improvement in left ventricular ejection fraction (36.7 ± 7.5 vs. 59.4 ± 9.7 %; P < 0.001). The mean left ventricular end-diastolic diameter before treatment was 59.5 ± 8.3 mm (range, 43 to 70), compared with 51.9 ± 7.4 mm (range, 40 to 67) (P = 0.009) after 3 months follow-up. The levels of NT-proBNP decreased after ablation procedure, from 4,092.6 ± 3,916.6 to 478.9 ± 881.9 pg/ml (P < 0.001). After successful ablation, ventricular function normalized in 15 of 17 (88.2 %) patients at a mean of 3 months. CONCLUSIONS: Restoration of LV function and reversal of LV remodeling can be achieved with successful elimination of tachycardia in the majority of patients. NT-proBNP level elevates in subjects with TCM and decreases sharply after ablation.
OBJECTIVES:Tachycardia-induced cardiomyopathy (TCM) is a reversible cause of heart failure. Little is known of the characteristics of tachycardia associated with the development of left ventricular (LV) dysfunction and the reversal of cardiomyopathy after cure of tachycardia. This study aimed to examine the reversal of cardiomyopathy in patients undergoing ablation with congestive heart failure secondary to tachycardia. METHODS: A total of 625 patients underwent radiofrequency ablation for tachycardiarrhymias between January 2009 and July 2011. Echocardiography analysis was performed to identify patients with depressed LV function, defined as a left ventricular ejection fraction <50 %. Patients with preexisting structural heart disease (n = 10) were excluded. NT-pro-B-type natriuretic peptide (NT-proBNP) assessment was performed before ablation in patients considered to have TCM (n = 17). Repeated echocardiography study and NT-proBNP assessment were measured after a mean follow-up of 3 months. Levels of NT-proBNP before and after ablation were compared. Reversal of cardiomyopathy was also assessed. RESULTS: The incidence of TCM was 2.7 % (12 males; age, 35.8 ± 17.1 years). Successful ablation was performed in 16 of 17 patients (94.1 %). There was a significant improvement in left ventricular ejection fraction (36.7 ± 7.5 vs. 59.4 ± 9.7 %; P < 0.001). The mean left ventricular end-diastolic diameter before treatment was 59.5 ± 8.3 mm (range, 43 to 70), compared with 51.9 ± 7.4 mm (range, 40 to 67) (P = 0.009) after 3 months follow-up. The levels of NT-proBNP decreased after ablation procedure, from 4,092.6 ± 3,916.6 to 478.9 ± 881.9 pg/ml (P < 0.001). After successful ablation, ventricular function normalized in 15 of 17 (88.2 %) patients at a mean of 3 months. CONCLUSIONS: Restoration of LV function and reversal of LV remodeling can be achieved with successful elimination of tachycardia in the majority of patients. NT-proBNP level elevates in subjects with TCM and decreases sharply after ablation.
Authors: A G Manolis; A G Katsivas; E E Lazaris; C V Vassilopoulos; N E Louvros Journal: J Interv Card Electrophysiol Date: 1998-03 Impact factor: 1.900
Authors: Jose F Huizar; Karoly Kaszala; Jonathan Potfay; Anthony J Minisi; Edward J Lesnefsky; Antonio Abbate; Eleonora Mezzaroma; Qun Chen; Rakesh C Kukreja; Nicholas N Hoke; Leroy R Thacker; Kenneth A Ellenbogen; Mark A Wood Journal: Circ Arrhythm Electrophysiol Date: 2011-05-16
Authors: Can Hasdemir; Cem Ulucan; Oguz Yavuzgil; Alper Yuksel; Yildirim Kartal; Evrim Simsek; Oktay Musayev; Meral Kayikcioglu; Serdar Payzin; Hakan Kultursay; Mehmet Aydin; Levent H Can Journal: J Cardiovasc Electrophysiol Date: 2011-01-14
Authors: J T Harrigan; J J Kangos; A Sikka; K R Spisso; N Natarajan; D Rosenfeld; S Leiman; D Korn Journal: N Engl J Med Date: 1981-06-18 Impact factor: 91.245
Authors: Melissa J Byrne; Jai S Raman; Clif A Alferness; Murry D Esler; David M Kaye; John M Power Journal: J Card Fail Date: 2002-04 Impact factor: 5.712
Authors: Frederick A Tibayan; David T M Lai; Tomasz A Timek; Paul Dagum; David Liang; George T Daughters; Neil B Ingels; D Craig Miller Journal: J Thorac Cardiovasc Surg Date: 2002-07 Impact factor: 5.209
Authors: D L Packer; G H Bardy; S J Worley; M S Smith; F R Cobb; R E Coleman; J J Gallagher; L D German Journal: Am J Cardiol Date: 1986-03-01 Impact factor: 2.778